Lipids are key drivers in many metabolic disease indications. The most well-known lipid related diseases are cardiovascular complications, such as stroke and coronary artery disease. Lipids also affect liver diseases such as NASH and NAFLD but also several rare orphan diseases are intimately linked to lipid disturbances. Lipigon is currently focusing on developing innovative new therapies for such orphan diseases but with an outspoken possibility to expand into broader indications.


There is a need for new effective and safe alternatives or add-on treatments to statins in high risk patients with dyslipidemia. Statin treatment alone only lowers the CVD event risk by 25-30 %, leaving a considerable residual risk for the number one cause of morbidity and mortality in the world. One of the high-risk groups that are targeted is type 2 diabetic patients. The prevalence of diabetes is steadily increasing and is projected be above 400 million in 2030. Since almost 20% of diabetic patients have dyslipidemia, the number of patients with diabetic dyslipidemia will increase accordingly, presenting a vast market opportunity. Lipigon targets lipoprotein lipase (LPL); a clinical and genetically validated target for improving non-LDL dyslipidemia. LPL is an obvious target and acknowledged as a very difficult target, but with 50 years in the lipase research field we are the right company for the job.


Lipodystrophy is a rare disorder characterized by complete or partial lack of adipose tissue. This leads to an imbalance in fat distribution. In the absence of adipose tissue different organs accumulate fat and accelerates a broad spectrum of metabolic diseases, such as type 2 diabetes, cardiovascular disease and fatty liver diseases (NAFLD/NASH). Treatment options for these patients are few and not satisfying. About 2000 patients with generalized (GL) and partial lipodystrophy (PL) are estimated in the US and Europe together. For the larger PL population there are no approved treatments. Liver lipid accumulation is central in the progress of the disease. Lipigon’s goal is to break this viscous cycle, normalize liver lipid levels and restore normal liver function.


Familial chylomicronemia syndrome (FCS) is a rare and severe disorder characterized by elevated plasma triglycerides which, among several comorbidities, can cause recurrent episodes of acute pancreatitis – a potentially fatal state of sudden pancreas inflammation. Whereas FCS is very uncommon and often due to a known genetic mutation in the Lipoprotein Lipase (LPL) system, hypertriglyceridemia (HTG) is present in many patients. In some countries over 50 % of the adult population has elevated plasma triglycerides. The etiology is more of a mixed background (lifestyle and genetics) among these patients but the severe form (with fasting plasma triglycerides over 500mg/dL or 5 mmol/L) bares similar traits as FCS with a high risk for acute pancreatitis. Lipisense is a revolutionary new treatment that targets fasting plasma triglycerides via a mechanism that is first-in-class.